Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 13, Art. 81 (pp. 967-986)    |    2012       

»

Therapy and prevention of anemia and iron overload in myelodysplastic syndrome patients

Romanenko N.A

Russian Research Institute of Hematology and Transfusiology, Russian Federal Medico-biological Agency

Brief summary

In the lecture are presented WHO classification (2008) of myelodysplastic syndrome, IPSS and WPSS prognostic scoring scales, discussed any mechanisms of development anemia and the ways of its correction by red blood cells transfusion and recombinant epietin agents, and also shown possible factors of iron overload development and the ways of its prevention and treatment.


Key words

myelodysplastic syndrome, anemia, erythropoietin, epoetin alfa, hemoglobin, red blood cells transfusion, iron overload

Reference list

1. Frenkel M.A., Shirin A.D. Sovremennaya diagnostika mielodisplastiche- skih sindromov vzroslih (klassifikaciya VOZ 2008 g.)// Klin.onkogematol.- 2010.- T.3, №3.- S. 243-251.


2. Sanz G.F., Sanz M.A., Vallespi T. et al. Two regression models and scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients// Blood.- 1989.- Vol.74, No1.- P. 395-408.


3. Vardiman J.M., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes// Blood.- 2009.- Vol.114, No5.- C. 937-951.


4. Romanenko N.A., Abdylkadirov K.M. Patogeneticheskaya korrekciya anemii eritropoezstimyliryushimi preparatami y bolnih limfoproliferativnimi zaboleva- niyami// Onkogematologiya.- 2011.- №3.- S. 39-49.


5. Leitch H.A., Vickars L.M. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?// Hematology Am. Soc. Hematol. Educ. Program.- 2009.- P. 664-672.


6. Germing U., Hildebrandt B., Pfeilstöcker M. et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)// Leukemia.- 2005.- Vol. 19, No 12.- P. 2223-2231.


7. Murphy M.F., Wallington T.B., Kelsey P. et al. Guidelines for the clinical use of red cell transfusions// Br J of Haematol.- 2001.- Vol. 113.- P.24-31.


8. Romanenko N.A. Study of efficacy red cell transfusions and their influencing on quality of life in hematological malignancies patients with anemia// Haematologica – The Hematology journal.- 2012.- Vol. 97, Suppl.1.- P.163.


9. Cvetaeva N.V., Levina A.A., Mamykova U.I. Osnovi regylyacii obmena je- leza// Klin.onkogematol.- 2010.- T.3, №3. S. 278-283.


10. Pigeon C., Ilyin G., Courselaud B. et al. A new mouse liver-specific protein homologous to human antibacterial peptid hepcidin is overexpressed during iron jverload// J. Biol. Chem.- 2001.- Vol. 276.- P.7811-7819.


11. Goldberg S.L. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes// Leuk Res.- 2007.- Vol. 31, Suppl 3.- S. 16-22.


12. Takatoku M., Uchiyama T., Okamoto S. et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality// Eur J Haematol.- 2007.- Vol.78.- P.487–494.


13. Gricaev S.V., Abdylkadirov K.M. Effektivnost helatornoi terapii bol- noi mielodisplasticheskim sindromom// Klin.onkogematol.- 2011.- T.4, №4.- S.311-314.


14. Elliot S., Sinclair A.M. The effect of erythropoietin on normal and neoplastic cellc// Biologics: Targets and Therapy.- 2012.- Vol.6.- P.163-189.


15. Brines M.L., Ghezzi P., Keenan S. et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury// Proc Natl Acad Sci USA.- 2000.- Vol.97, No19.- P.10526–10531.


16. Hayashi T., Suzuki A., Shoji T. et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure// Am. J. Kidney. Dis.- 2000.- Vol.35, No2.- P.250–256.


17. Kaptanoglu E., Solaroglu I., Okutan O. et al. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings// Neurosurg. Rev.- 2004.- Vol.27, No2.- 113–120.


18. Kumral A., Uysal N., Tugyan Ket al. Erythropoietin improves longterm spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats// Behav. Brain Res.- 2004.- Vol.153, No1.- P.77–86.


19. Parsa C.J., Matsumoto A., Kim J. et al. A novel protective effect of erythropoietin in the infarcted heart// J. Clin. Invest.- 2003.- Vol. 112, No7.- P.999–1007.


20. Rizzo J.D., Brouwers M., Hurley P. et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer// Blood.- 2010.- Vol. 116, No20.- P.4045-4059.


21. Cheson B.D., Bennett J.M., Kantarjian H. et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes// Blood.- 2000.- Vol.96, No12.- P. 3671–3674.


22. Cheson B.D., Greenberg P.L., Bennett J.M. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia// Blood.- 2006.- Vol.108, No2.- P.419–425.


23. Jadersten M., Malcovati L., Dybedal I. et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome// J Clin Oncol.- 2008.- Vol.26, No21.- P. 3607–3613.


24. Park S., Grabar S., Kelaidi C. et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience// Blood.- 2008.- Vol.111, No2.- P. 574–582.


25. Villegas A., Arrizabalaga B., Fernbndez-Lago C. et al. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response// Curr. Med. Res. Opin.- 2011.- Vol. 27, No5.- P.951-960.


26. Azzara A., Carulli G., Galimberti S. et al. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution// Am J Hematol.- 2011.- Vol.86, No9.- P.762-767.


27. Crisa E., Foli C., Passera R. et al Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13- cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival// Br J Haematol.- 2012.- Vol.158, No1.- P.99-107.


28. Ferrero D., Darbesio A., Giai V. et al. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes// Br. J. Haematol.- 2009.- 144, No3.- P. 342-349.


29. Itzykson R., Ayari S., Vassilief D. et al. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin inmyelodysplastic syndromes? A report on 59 cases// Leukemia.- 2009.- Vol.23, No4.- P. 673-678.


30. Bennett C.L., Silver S.M., Djulbegovic B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia// JAMA.- 2008.- Vol. 299, No8.- P.914–924.


31. Khorana A.A., Francis C.W., Blumberg N. et al. Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients with Cancer// Arch. Intern. Med.- 2008.- Vol.168, No21.- P.2377-2381.


32. Hershman D.L., Buono D.L., Malin J. et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer// J. Natl. Cancer. Inst.- 2009.- Vol.101, No23.- P.1633-1641.